# US 2004/0082020 A1 · Hyperglycosylated hCG (invasive trophoblast antigen) in differential diagnosis of malignant or invasive trophoblastic disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082020 A1
- Document ID: US20040082020A1
- Status: Published application
- Kind: A1
- Application number: 10/616,323
- Filed: 2003-07-09
- Published: 2004-04-29
- Earliest claimed: 2002-10-10
- Assignees: University of New Mexico
- Inventors: Laurence A. Cole
- Web page: https://patentgrep.com/patent/US20040082020A1

## CPC

- G01N 33/5755: of the uterine cervix, uterine corpus or endometrium
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- G01N 33/76: Human chorionic gonadotropin {including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides methods for detecting the presence or absence of invasive trophoblast cells. In addition, the invention provides methods for distinguishing quiescent trophoblast diseases from invasive trophoblast diseases and methods for monitoring progression of quiescent trophoblast diseases. The invention provides methods for detecting the presence or absence of germ cell tumors.

## Claims

### Claim 1

A method of detecting the presence or absence of invasive trophoblast cells in a biological sample comprising the steps of:
a. obtaining a biological sample from a patient;
b. measuring an amount of hCG in the biological sample;
c. measuring an amount of ITA in the biological sample; and
d. determining the percentage of hCG that is ITA, wherein invasive trophoblast cells are detected if the percentage is 30% or greater.

### Claim 2 (depends on 1)

The method of claim 1, wherein the hCG is a subunit of hCG.

### Claim 3 (depends on 2)

The method of claim 2, wherein the subunit is α hCG or β hCG.

### Claim 4 (depends on 1)

The method of claim 1, wherein the hCG is intact hCG.

### Claim 5 (depends on 1)

The method of claim 1, wherein the hCG is total hCG.

### Claim 6 (depends on 1)

The method of claim 1, wherein the patient is a woman previously diagnosed as having a gestational trophoblastic disease.

### Claim 7 (depends on 6)

The method of claim 6, wherein the gestational trophoblastic disease is hydatidiform mole.

### Claim 8 (depends on 6)

The method of claim 6, wherein the gestational trophoblastic disease is choriocarcinoma.

### Claim 9 (depends on 6)

The method of claim 6, wherein the gestational trophoblastic disease is placentasite trophoblastic tumor.

### Claim 10 (depends on 1)

The method of claim 1, wherein the biological sample is urine, saliva, plasma, or serum.

### Claim 11 (depends on 10)

The method of claim 10 wherein the biological sample is urine.

### Claim 12 (depends on 1)

A method of diagnosing quiescent gestational trophoblastic disease in a patient comprising the method of claim 1, wherein the patient has persistently low hCG titers, and wherein quiescent gestational trophoblastic disease is diagnosed if the percentage of hCG that is ITA determined in step (d) is less than 30%.

### Claim 13 (depends on 12)

The method of claim 12, wherein the patient is a woman previously diagnosed as having a gestational trophoblastic disease.

### Claim 14 (depends on 13)

The method of claim 13, wherein the gestational trophoblastic disease is hydatidiform mole.

### Claim 15 (depends on 13)

The method of claim 13, wherein the gestational trophoblastic disease is choriocarcinoma.

### Claim 16 (depends on 13)

The method of claim 13, wherein the gestational trophoblastic disease is placentasite trophoblastic tumor.

### Claim 17

A method of detecting the presence or absence of invasive trophoblast cells in a biological sample comprising the steps of:
a. obtaining a biological sample from a patient; and
b. measuring an amount of ITA in the biological sample; wherein invasive trophoblast cells are detected if the amount of ITA in the biological sample is 2 IU/L or greater.

### Claim 18

A method of monitoring the progression of quiescent gestational trophoblastic disease comprising the steps of:
a. obtaining a biological sample from a patient diagnosed as having quiescent gestational trophoblastic disease;
b. measuring an amount of hCG in the biological sample;
c. repeating steps (a) and (b) with a biological sample obtained at subsequent time points;
d. measuring an amount of ITA in a biological sample from step (c) if the amount of hCG in a biological sample from step (c) is higher than the amount of hCG in step (b); and
e. determining the percentage of hCG that is ITA in the biological sample from step (d).

### Claim 19 (depends on 18)

The method of claim 18, wherein the hCG is a subunit of hCG.

### Claim 20 (depends on 19)

The method of claim 19, wherein the subunit is α hCG or β hCG.

### Claim 21 (depends on 18)

The method of claim 18, wherein the hCG is intact hCG.

### Claim 22 (depends on 18)

The method of claim 18, wherein the hCG is total hCG.

### Claim 23

A method of detecting the presence or absence of a germ cell tumor in a biological sample comprising the steps of:
a. obtaining a biological sample from a patient;
b. measuring an amount of hCG in the biological sample;
c. measuring an amount of ITA in the biological sample; and
d. determining the percentage of hCG that is ITA, wherein a germ cell tumor is detected if the percentage is 30% or greater.

### Claim 24 (depends on 23)

The method of claim 23, wherein the hCG is a subunit of hCG.

### Claim 25 (depends on 24)

The method of claim 24, wherein the subunit is α hCG or β hCG.

### Claim 26 (depends on 23)

The method of claim 23, wherein the hCG is intact hCG.

### Claim 27 (depends on 23)

The method of claim 23, wherein the hCG is total hCG.

### Claim 28 (depends on 23)

The method of claim 23, wherein the germ cell tumor is an ovarian germ cell tumor.

### Claim 29 (depends on 28)

The method of claim 28, wherein the ovarian germ cell tumor is dysgerminoma.

### Claim 30 (depends on 23)

The method of claim 23, wherein the germ cell tumor is a testicular germ cell tumor.

### Claim 31 (depends on 30)

The method of claim 30, wherein the testicular germ cell tumor is seminoma or choriocarcinoma.

### Claim 32

A method of detecting the presence or absence of a germ cell tumor in a biological sample comprising the steps of:
a. obtaining a biological sample from a patient; and
b. measuring an amount of ITA in the biological sample; wherein a germ cell tumor is detected if the amount of ITA in the biological sample is 2 IU/L or greater.

### Claim 33 (depends on 32)

The method of claim 32, wherein the germ cell tumor is an ovarian germ cell tumor.

### Claim 34 (depends on 33)

The method of claim 33, wherein the ovarian germ cell tumor is dysgerminoma.

### Claim 35 (depends on 32)

The method of claim 32, wherein the germ cell tumor is a testicular germ cell tumor.

### Claim 36 (depends on 35)

The method of claim 35, wherein the testicular germ cell tumor is seminoma or choriocarcinoma.

### Claim 37

A method of monitoring the progression of a germ cell tumor comprising the steps of:
a. obtaining a biological sample from a patient diagnosed as having a germ cell tumor;
b. measuring an amount of hCG in the biological sample;
c. repeating steps (a) and (b) with a biological sample obtained at subsequent time points;
d. measuring an amount of ITA in a biological sample from step (c) if the amount of hCG in a biological sample from step (c) is higher than the amount of hCG in step (b); and
e. determining the percentage of hCG that is ITA in the biological sample from step (d).

### Claim 38 (depends on 37)

The method of claim 37, wherein the hCG is a subunit of hCG.

### Claim 39 (depends on 38)

The method of claim 38, wherein the subunit is α hCG or β hCG.

### Claim 40 (depends on 37)

The method of claim 37, wherein the hCG is intact hCG.

### Claim 41 (depends on 37)

The method of claim 37, wherein the hCG is total hCG.

### Claim 42 (depends on 37)

The method of claim 37, wherein the germ cell tumor is an ovarian germ cell tumor.

### Claim 43 (depends on 42)

The method of claim 42, wherein the ovarian germ cell tumor is dysgerminoma.

### Claim 44 (depends on 37)

The method of claim 37, wherein the germ cell tumor is a testicular germ cell tumor.

### Claim 45 (depends on 44)

The method of claim 44, wherein the testicular germ cell tumor is seminoma or choriocarcinoma.
